A number of other research analysts have also issued reports on the company. Cantor Fitzgerald lifted their target price on Emergent Biosolutions from $68.00 to $75.00 and gave the company an overweight rating in a report on Friday, November 2nd. Goldman Sachs Group upgraded Emergent Biosolutions from a neutral rating to a buy rating and lifted their target price for the company from $60.00 to $75.00 in a report on Friday, November 2nd. Chardan Capital lifted their target price on Emergent Biosolutions from $60.00 to $66.00 and gave the company a buy rating in a report on Tuesday, September 4th. Cowen reiterated a hold rating and issued a $49.00 target price on shares of Emergent Biosolutions in a report on Wednesday, August 29th. Finally, Wells Fargo & Co set a $65.00 target price on Emergent Biosolutions and gave the company a hold rating in a report on Wednesday, August 29th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $66.25.
NYSE:EBS traded down $0.02 during midday trading on Friday, reaching $67.54. The company had a trading volume of 285,122 shares, compared to its average volume of 370,379. The firm has a market cap of $3.54 billion, a PE ratio of 35.55, a price-to-earnings-growth ratio of 1.58 and a beta of 1.27. Emergent Biosolutions has a 12-month low of $36.38 and a 12-month high of $71.01. The company has a current ratio of 5.52, a quick ratio of 4.29 and a debt-to-equity ratio of 0.01.
Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.55 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.62 by ($0.07). The company had revenue of $173.70 million during the quarter, compared to analysts’ expectations of $185.16 million. Emergent Biosolutions had a net margin of 14.19% and a return on equity of 12.89%. The company’s revenue for the quarter was up 16.3% on a year-over-year basis. During the same quarter last year, the business posted $0.73 earnings per share. Equities analysts forecast that Emergent Biosolutions will post 2.2 EPS for the current year.
In other Emergent Biosolutions news, EVP Adam Havey sold 22,996 shares of Emergent Biosolutions stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $61.06, for a total transaction of $1,404,135.76. Following the completion of the sale, the executive vice president now directly owns 36,079 shares of the company’s stock, valued at approximately $2,202,983.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathryn C. Zoon sold 4,242 shares of Emergent Biosolutions stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $69.74, for a total value of $295,837.08. Following the sale, the director now directly owns 33,972 shares of the company’s stock, valued at $2,369,207.28. The disclosure for this sale can be found here. Insiders have sold a total of 199,943 shares of company stock valued at $12,115,228 over the last ninety days. 16.50% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in EBS. BlackRock Inc. lifted its holdings in Emergent Biosolutions by 18.2% during the 3rd quarter. BlackRock Inc. now owns 6,350,905 shares of the biopharmaceutical company’s stock worth $418,078,000 after buying an additional 978,194 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Emergent Biosolutions by 10.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,066,511 shares of the biopharmaceutical company’s stock worth $104,338,000 after buying an additional 198,600 shares during the last quarter. FMR LLC lifted its holdings in Emergent Biosolutions by 192.7% during the 2nd quarter. FMR LLC now owns 290,507 shares of the biopharmaceutical company’s stock worth $14,668,000 after buying an additional 191,248 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in Emergent Biosolutions by 18.1% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,141,021 shares of the biopharmaceutical company’s stock worth $57,610,000 after buying an additional 174,614 shares during the last quarter. Finally, Prudential Financial Inc. lifted its holdings in Emergent Biosolutions by 86.1% during the 3rd quarter. Prudential Financial Inc. now owns 336,554 shares of the biopharmaceutical company’s stock worth $22,156,000 after buying an additional 155,666 shares during the last quarter. 82.76% of the stock is owned by institutional investors.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Read More: Market Capitalization
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.